RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 RE-VERSE AD
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 21
SP 4
OP 5
DO 10.1177/1559897715599362
UL http://mdc.sagepub.com/content/15/21/4.abstract
AB In the open-label, phase 3 RE-VERSE AD trial, idarucizumab resulted in complete reversal of dabigatran-related anticoagulation in up to 88% of patients with uncontrolled bleeding or who required an emergent procedure, with no safety concerns. The median maximum reversal of 100% occurred within 4 hours and was evident within minutes after the first of 2 idarucizumab infusions.